Background: It is unclear whether plant stanols lower serum LDLcholesterol concentrations and cholesterol-standardized fat-soluble antioxidant concentrations dose-dependently when consumption exceeds the recommended daily intakes of 2.0-3.0 g. Objective:
INTRODUCTION
It is well documented that free and esterified plant stanols and sterols, when incorporated into a wide variety of different foods, effectively lower LDL cholesterol (1) . In fact, several metaanalyses have already been performed to combine the many studies in this field. From some of these meta-analyses, it was concluded that there is little additional benefit when daily intakes of plant stanols or sterols exceed 2.5 g (1) (2) (3) . In contrast, we recently published a meta-analysis that did suggest that the dose-response relation between dietary plant stanols with serum LDL-cholesterol concentrations was linear, at least for intakes up to 4 g/d (4) . Because many patients treated for hypercholesterolemia do not reach optimal LDL-cholesterol concentrations, it is important to examine whether a daily intake of plant stanols or sterols above recommend intakes of 2 g/d (5) results in an extra LDL-cholesterol-lowering effect or not. At the same time, attention should be paid to other effects. It is known, for example, that serum concentrations of a-tocopherol and the hydrocarbon carotenoids b-carotene and lycopene are significantly lowered by plant sterol and stanol ester consumption. Part of the reduction can be ascribed to the decrease in the number of LDL particles, which are carriers of these antioxidants. However, after standardizing for serum total or LDL cholesterol, the concentration of b-carotene was still significantly reduced, indicating that the absorption of this provitamin may be affected by the consumption of plant stanol or sterol esters (1, 6, 7) . However, dose-response relations have not been systematically evaluated. We therefore decided to study the relation between plant stanols at daily intakes of 0, 3, 6, and 9 g provided as plant stanol esters on changes in serum concentrations of LDL cholesterol and fat-soluble antioxidants. In addition, effects on plasma plant sterol, plant stanol, and cholesterol precursor concentrations were studied.
SUBJECTS AND METHODS

Subjects
Recruitment of subjects started in August 2007 via posters in the university and hospital buildings and by advertisements in local newspapers. Also, men and women who had participated in earlier studies at the Department of Human Biology (Maastricht University) were approached. Subjects came to the university for 2 screening visits with an interval of 3 d. On both visits, fasting blood was sampled for analyses of serum lipids and lipoproteins. In addition, height and body weight were determined. Furthermore, subjects had to complete a medical and general questionnaire. Inclusion criteria were as follows: age between 18 and 70 y; mean serum total cholesterol concentrations between 5 and 8 mmol/L; no active cardiovascular disease (eg, acute myocardial infarction and cerebrovascular accident) during the previous 6 mo; no type 1 or 2 diabetes; no severe medical conditions that could interfere with the study, such as epilepsy, asthma, chronic obstructive pulmonary disease, inflammatory bowel diseases, cancer, and rheumatoid arthritis; no use of cholesterol-lowering medication or diuretics; no weight gain or loss .3 kg during the past 3 mo; no self-reported abuse of drugs or consumption of ,2 alcoholic drinks/d. Finally, subjects could not have participated in another biomedical study within 1 mo before the start of the study, and none of the women were pregnant or breastfeeding. After screening, 97 subjects met all our criteria and started the study. Three subjects dropped out during the course of the study for reasons not related to the study protocol. Furthermore, one subject was excluded because of poor compliance. Thus, 93 subjects completed the study successfully.
All subjects were informed about the nature and risk of the experimental procedures before their written informed consent was obtained. The Ethics Committee of the Maastricht University had approved the protocol before the start of the study.
Diets and design
Subjects were asked to replace their own spread with margarines, of which 20 g/d had to be consumed, divided over 2 meals. In addition, subjects had to consume daily, on 2 different occasions, 2 cups of soy-based yogurt. Each cup provided 150 mL. For the first 3 wk (run-in period), subjects used margarine and soy-based yogurt without added plant stanol esters. At the end of the run-in period, subjects were randomly allocated to 1 of the 4 experimental groups, stratified for sex, age, and BMI. Baseline characteristics of the subjects before the start of the study are shown in Table 1 . For the next 4 wk, the first group continued with the products without added plant stanol esters, the second group received plant stanol ester-enriched margarine and soy-based yogurt without added plant stanol esters, the third group received margarine without added plant stanol esters and a plant stanol ester-enriched soy-based yogurt, and the last group received margarine and soy-based yogurt, both enriched with plant stanol esters ( Figure 1 ). In this way, the targeted daily intakes of plant stanols in the 4 groups were 0, 3, 6, and 9 g, respectively. Groups are referred to as the control group, 3-g group, 6-g group, and 9-g group. Plant stanols were provided as fatty acid esters, made by transesterification of free plant stanols with rapeseed oil fatty acids. The plant stanols were derived from wood sterols with '10% of vegetable oil-derived plant sterols (Raisio Nutrition Ltd, Turku, Finland). The plant stanol ester blend contained mainly sitostanol (79%) and campestanol esters (16%). Because the composition of the soy-based yogurt with and without added plant stanol esters differed slightly, it was decided to make 4 different margarines so that total energy and fat intake as provided by the experimental products were much as comparable as possible across the 4 groups ( Table 2) . The margarine was packed in tubs of 140 g each, equivalent to the amount of margarine for 7 d, and was used as spread. Subjects were instructed to consume 1 cup of soy-based yogurt at lunch and one cup at dinner. All products, which were made by Raisio Nutrition Ltd (Turku, Finland), were coded with a color label to blind the subjects and the investigators. The volunteers came to the university at least every 2 wk to receive the products and for measuring body weight (without shoes and heavy clothing). At the end of the week, the used tubs and unused cups of the soy-based yogurt had to be set aside and returned to the department to be weighed back to estimate the weekly intake of experimental products. At the end of the study, this information was used to estimate the average daily intake. At the end of the run-in and experimental periods, the subjects completed a food-frequency questionnaire (8) in which they recorded their food intake from the previous 3 wk. A dietitian checked these questionnaires in the presence of the subjects and calculated the energy and nutrient intakes of the subjects using the Dutch food-composition tables. In a diary, the subjects had to write down any signs of illness, changes in medication, and the amount of margarine and soy-based yogurt used per day. In addition, subjects were asked not to change their habitual diet, level of physical exercise, smoking habits, or use of alcohol during the study.
Blood sampling
Fasting blood samples were taken by venipuncture at the start of the study, at weeks 2 and 3 (run-in period), and at weeks 6 and 7 (experimental period). All venipunctures were generally carried out by the same person, at the same location, and at the same time of the day (between 0745 and 1030). Blood samples were taken from a forearm vein by using evacuated tubes under minimal stasis with the subject in a supine position. On the morning of sampling, subjects were not allowed to smoke, eat, or drink (except water). Volunteers were fasting since 2200 the day preceding blood sampling.
Blood was sampled in 10-mL serum separator tubes for analysis of lipids and lipoproteins, antioxidants, and clinical safety measurements. Serum tubes were kept at room temperature after blood sampling. At least 1 h after venipuncture, serum was obtained by centrifuging at 2000 3 g for 30 min at 4°C, portioned into aliquots, and stored at 280°C. At the same time, 10-mL EDTA-coated tubes were drawn for analysis of plant sterol, stanols, and cholesterol precursors. Plasma was obtained immediately by centrifugation at 2000 3 g for 30 min at 4°C, portioned into aliquots, and stored at 280°C.
Lipids and apolipoproteins
In all samples, serum total cholesterol (CHOD-PAP method; Roche), HDL cholesterol (precipitation method; Roche), and triacylglycerols with correction for free glycerol (GPO Trinder; Sigma Diagnostics) were analyzed. LDL cholesterol was calculated by using the Friedewald formula (9) . All samples from one subject were analyzed within the same run.
Lipid-soluble antioxidants
Samples from days 14 and 21 and from days 42 and 49 were pooled before the analyses. Serum concentrations of a-tocopherol, b-carotene, canthaxanthin, zeaxanthin, and lutein were quantified by reversed-phase HPLC according to Van Vliet et al (10) and modified by Vaisman et al (11) . Briefly, serum samples were extracted with hexane. The hexane layer was evaporated to dryness and dissolved in a mixture of methanol and acetonitrile (1:1). This was injected onto a reversed-phase column, which was eluted with a gradient consisting of methanol, acetonitrile, 2-propanol, and water at a flow rate of 1.5 mL/min. A diode-array detector was used for detection. All samples from one subject were analyzed within the same analytic run. The results were also expressed per mmol serum cholesterol.
Plasma plant sterols, stanols, and cholesterol precursors
Plasma plant sterol (sitosterol and campesterol), plant stanol (sitostanol and campestanol), cholesterol precursor (lathosterol), and cholesterol concentrations were analyzed by gas-liquid chromatography-mass spectrometry (GC-MS) as described previously (12) . Samples from days 14 and 21 and from days 42 and 49 were pooled before analyses. All samples from one subject were analyzed within the same sequence. The results were also expressed per mmol plasma total cholesterol. 1 Differences between treatment groups were analyzed by one-factor ANOVA or chi-square tests and were not statistically significant (P . 0.05).
2 Mean 6 SD (all such values). 
Markers for liver and kidney function and inflammation
Serum samples from days 21 and 49 were analyzed to determine indicators of kidney function (creatinine) and liver function (alkaline phosphatase, alanine transaminase, c-glutamyl transpeptidase, aspartate aminotransferase, and total bilirubin concentrations). These measurements were carried out on a Beckman Coulter Synchron LX20 PRO Clinical System (Beckman Coulter Inc, Fullerton, CA). High-sensitivity Creactive protein (hs-CRP) concentrations were measured with a highly sensitive immunoturbidimetric assay (Kamiya Biomedical Company, Seattle, WA). All samples from one subject were analyzed in the same analytic run.
Statistics
Differences in baseline characteristics between the diet groups were examined by one-factor analysis of variance (ANOVA) or chi-square tests. Responses to treatment of each subject were calculated as the difference between values obtained at the end of the experimental period. If samples were not pooled before analyses, mean values from weeks 6 and 7 (experimental period) and from weeks 2 and 3 (run-in period) were first calculated. Differences in changes between the diet groups were analyzed by ANOVA. In addition, the mean change in each amount of intake (except the mean of the control group) was compared with the mean change in the previous amount of intake. Because this involved 3 comparisons, the level of statistical significance was set at 0.017 3 3 by using the Bonferroni multiple comparisons test. Regression analysis was used to examine linearity or nonlinearity between intake and changes. First, a quadratic model was fitted. When the quadratic component was not statistically significant, the analyses were repeated with the linear component only.
Values are expressed as means 6 SDs, unless stated otherwise. However, indexes of kidney and liver function and of hs-CRP concentrations were not normally distributed, as indicated by Shapiro-Wilk tests. These indexes were therefore analyzed according to the nonparametric Kruskal-Wallis test and are presented as medians (ranges). All statistical analyses were performed with SPSS 16.0 for Mac Os X (SPSS Inc, Chicago, IL).
RESULTS
Dietary intakes, margarine consumption, and body weight
Energy intake; the proportions of energy from carbohydrates, fatty acids, and proteins; and cholesterol intake were comparable between the groups and did not change significantly during the study (see the supplemental table under ''Supplemental data'' in the online issue). Mean estimated daily intakes of the margarines and soy-based yogurts were slightly lower than the targeted 1 SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids. 2 Plant stanols (sitostanol: 79%; campestanol: 16%) were provided as fatty acid esters. The subjects were requested to consume 20 g margarine and 300 mL soy-based yogurt daily. The estimated mean (6SD) daily intakes of plant stanols were 2.80 6 0.68 g for the 3-g group, 5.75 6 0.36 g for the 6-g group, and 8.70 6 0.51 g for the 9-g group. amounts of 20 g and 300 mL, respectively. This resulted in estimated mean daily intakes of plant stanols for the 3 experimental groups of 2.80 6 0.68, 5.75 6 0.36, and 8.70 6 0.51 g, respectively. During the study, body weight changed in the control group by 0.2 6 0.8 kg, in the 3-g group by 0.10 6 0.7 kg, in the 6-g group by 0.3 6 1.0 kg, and in the 9-g group by 20.1 6 0.9 kg. These values did not differ significantly (P ¼ 0.473 for diet effect). Inspections of the diaries did not indicate any deviations from the protocol that may have affected the results.
Serum lipids and lipoproteins
When compared with the control group, plant stanol esters lowered serum LDL-cholesterol concentrations by 0.32 mmol/L (7.5%) in the 3-g group (P ¼ 0.005; Table 3 ). An intake of 6 g plant stanols caused an additional nonsignificant decrease of 4.5%. However, in the 9-g group, a further statistically significant decrease of 5.4% was evident. Thus, compared with the control group, serum LDL-cholesterol concentrations were lowered by 17.4% in the 9-g group. Changes in serum total cholesterol concentrations paralleled those in LDL cholesterol. HDL cholesterol and triacylglycerol did not change significantly. Consequently, the ratio of total to HDL cholesterol also showed a progressive continuous decrease when the intake of plant stanol esters was increased. For total cholesterol, LDL cholesterol, and the ratio of total to HDL cholesterol, a statistically significant linear trend between intakes with changes was found.
Antioxidants
The effects of increasing plant stanol esters intakes on serum lipid-soluble antioxidant concentrations are presented in Figure  2 . For a-tocopherol, a significant diet effect was found (P , 0.001). Compared with the previous intake amount, changes were 21.8 lmol/L (or 25.5%) for the 3-g group, 23.0 lmol/L (or 26.9%) for the 6-g group, and 20.4 lmol/L (or 23.8%) for the 9-g group. Only the difference in changes between the 6-g and 3-g groups was significant. For b-carotene, the diet effect was nearly significant (P ¼ 0.082). Differences in absolute changes between groups, however, were not statistically significant. Compared with the previous intake amount, these 1 Diet effects were examined by one-factor ANOVA. In addition, the mean change in each amount of intake (except for the control group) was compared with the mean change in the previous amount of intake. Because this involved 3 comparisons, the level of statistical significance was set at 0.017 3 3 by using the Bonferroni multiple comparisons test. Finally, regression analysis was used to examine linearity between intake and changes. With this latter approach, the quadratic component was not statistically significant (P . 0.05). changes were 20.06 lmol/L (or 213.3%) for the 3-g group, 20.01 lmol/L (or 24.0%) for the 6-g group, and 20.05 lmol/L (or 27.3%) for the 9-g group. For lutein, the diet effect was not significant (P ¼ 0.214). For all these 3 antioxidants, a statistically significant linear trend between intakes with changes was found. Effects on canthaxanthin and zeaxanthin were comparable with those of b-carotene (data not shown).
Because lipid-soluble antioxidants are carried by lipoproteins, differences can be due to changes in the number of carrier particles, the lipoproteins. Concentrations were therefore also standardized for plasma total cholesterol concentrations. As is evident in Table 4 , the differences between the subsequent groups in cholesterol-standardized concentrations of these lipidsoluble antioxidants were not statistically different. Because of the large variation in response, even the change in cholesterolstandardized cholesterol concentrations for b-carotene of 20.01 lmol/mmol cholesterol (or 29.2%) for the 3-g compared with the control group was not statistically significant. Cholesterolstandardized concentrations of canthaxanthin and zeaxanthin did also not change (data not shown). The left y axis refers to a-tocopherol, and the right y axis refers to b-carotene and lutein. Diet effects were examined by one-factor ANOVA. In addition, the mean change in each amount of intake (except for the control group) was compared with the mean change in the previous amount of intake. Because this involved 3 comparisons, the level of statistical significance was set at 0.017 3 3 by using the Bonferroni multiple comparisons test. *Significantly different from the previous amount of intake, P , 0.05. 1 Diet effects were examined by one-factor ANOVA. In addition, the mean change in each amount of intake (except for the control group) was compared with the mean change in the previous amount of intake. Because this involved 3 comparisons, the level of statistical significance was set at 0.017 3 3 by using the Bonferroni multiple comparisons test. Finally, regression analysis was used to examine linearity between intake and changes. With this latter approach, the quadratic component was not statistically significant (P . 0.05). 2 Mean 6 SD (all such values).
Plant sterols, stanols, and cholesterol precursors
As expected, plant stanol ester consumption decreased plasma plant sterol (sitosterol and campesterol) concentrations ( Figure  3) . However, only the difference in changes between the 3-g and control groups was statistically significant. For plasma plant stanols (sitostanol and campestanol), a gradual increase was observed, and only the difference in changes for plasma sitostanol concentrations between the 6-g and 3-g groups was not statistically significant. Using regression analysis, we found that for sitosterol (P ¼ 0.003), campesterol (P , 0.001), sitostanol (P ¼ 0.003), and campestanol (P ¼ 0.033), the quadratic component was statistically significant, which suggested that the effects leveled off at higher intakes. Changes between the groups were not statistically significant for plasma lathosterol concentrations, but were linear with intakes (P ¼ 0.038).
Because these sterols are carried by lipoproteins, concentrations were standardized for plasma total cholesterol concentrations ( Table 5) . Cholesterol-standardized changes in plasma plant sterols are a marker of changes in cholesterol absorption, whereas changes in cholesterol-standardized concentrations of lathosterol reflect changes in endogenous cholesterol synthesis. Except for the changes between the 6-g and 3-g groups, the general observation was that cholesterol-standardized plasma plant sterol concentrations decreased when the intake of plant stanol esters increased. Effects leveled off at higher intakes, as the quadratic component was statistically significant. In contrast, cholesterol-standardized concentrations of the plant stanols increased with increasing intakes. After the regression analysis, the quadratic component was statistically significant for cholesterol-standardized sitostanol concentrations. Although cholesterol-standardized plasma lathosterol concentrations gradually increased at increasing intakes of plant stanols and were linearly related with intakes, differences between the groups were not statistically significant.
Side effects
Throughout the study, changes in indicators of kidney function (creatinine, P ¼ 0.946 for diet effect) and liver function (alkaline phosphatase, P ¼ 0.721; alanine transaminase, P ¼ 0.970; c-glutamyl transpeptidase, P ¼ 0.271; aspartate aminotransferase, P ¼ 0.091; and total bilirubin, P ¼ 0.056) were not related to plant stanol ester intake (data not shown). Also, hs-CRP concentrations did not change significantly (P ¼ 0.860). Six subjects had on one or more occasions hs-CRP concentrations .7 mg/L. When these subjects were excluded from the analysis, the conclusions did not change (P ¼ 0.423 for diet effect; data not shown).
DISCUSSION
Plant stanol esters are currently incorporated into a wide variety of functional foods with the aim of lowering LDLcholesterol concentrations. Recommended daily intakes of plant stanols are usually between 2 and 3 g, at which level the expected reduction in LDL cholesterol is '10% (1) (2) (3) (4) . It is thought that hardly any further reductions can be achieved at higher intakes (1-3). We have now shown for the first time that at daily intakes up to 9 g, the effects of plant stanols provided as their fatty acids lower LDL cholesterol in a dose-dependent linear way. Different food formats were used (margarine and soy-based yogurt). However, it is unlikely that this has affected the results, because Demonty et al (3) concluded from their meta-analysis that the LDL cholesterol-lowering effect of plant sterols and stanols when incorporated into dairy and nondairy food formats, or into nonfat-based and fat-based food formats, were comparable.
At the highest intake, LDL cholesterol was lowered by 17.4%, which agrees very well with the reduction of 17.1% reported by Gylling et al (13) after a daily intake of 8.8 g plant stanols. However, in that study, no dose-response relations were established. Interestingly, at these intakes, effects were not very different from those obtained by the pharmaceutical cholesterol absorption inhibitor ezetimibe, which lowers LDL cholesterol by 15-25%, both as monotherapy and in combination with statin and fibrate treatments (14) .
In line with most studies at lower intakes, serum HDLcholesterol and triacylglycerol concentrations remained unchanged FIGURE 3 . Mean (6SE) plasma plant sterol, stanol, and cholesterol precursor concentrations at the end of the run-in period (A) and changes after consumption of no (control group; n ¼ 22), 3 g (n ¼ 24), 6 g (n ¼ 22), or 9 g (n ¼ 25) plant stanols for 4 wk (B). Diet effects were examined by one-factor ANOVA. In addition, the mean change in each amount of intake (except for the control group) was compared with the mean change in the previous amount of intake. Because this involved 3 comparisons, the level of statistical significance was set at 0.017 3 3 by using the Bonferroni multiple comparisons test. * , **Significantly different from the previous amount of intake: *P , 0.05, **P , 0.001. in this population of mildly hypercholesterolemic subjects (5) . However, we showed previously that plant stanol esters may also lower serum triacylglycerol concentrations. This effect appeared to be dose-dependent at daily intakes up to 4.0 g and was especially evident in subjects with elevated baseline serum triacylglycerol concentrations (4). Although we observed in the present study slight reductions in serum triacylglycerol in all supplemented groups, the changes were not statistically significant. In theory, a decrease of 20.16 mmol/L could be expected in the 9-g group (4) . It is possible, however, that the effects on serum triacylglycerol were not proportional with intakes. It is also possible that baseline triacylglycerol concentrations in our population were too low to observe any statistically significant changes at all, because the study was not designed to look for effects on serum triacylglycerol. In fact, we recently reported that a daily plant stanol intake of 2 g lowered serum triacylglycerol concentrations by 29% in subjects with the metabolic syndrome (15) , who frequently have a disturbed triacylglycerol metabolism. Furthermore, the analyses suggested that a reduced hepatic VLDL-1 production might underlie these effects. Comparable effects were observed in normolipidemic subjects (16) . It can now be questioned whether the already low VLDL-1 concentrations in our nonhypertriglyceridemic subjects can be further lowered at daily plant stanol intakes exceeding 4.0 g. However, these considerations warrant further study.
When considering the applicability of higher than currently recommended intakes of plant stanol esters in the general population, 2 other aspects need to be considered. The first aspect that needs to be considered are changes in serum fat-soluble antioxidants. An important reason for the current daily recommendations of 2 g plant stanols relates to their lowering effects on serum carotenoid concentrations (5) . We postulated previously that the reductions in lipophylic hydrocarbon carotenoids (a 1 b-carotene and lycopene) at daily intakes of 3.8 or 4.0 g are particularly related to the reduced cholesterol absorption and to a smaller extent to the reduced serum total cholesterol concentrations (lipoproteins are the carriers of the carotenoids) (7) . On the basis of this finding, it was expected that a larger reduction in serum LDL cholesterol caused by a higher intake of plant stanols-assuming that the effect on LDL cholesterol 1 Diet effects were examined by one-factor ANOVA. In addition, the mean change in each amount of intake (except for the control group) was compared with the mean change in the previous amount of intake. Because this involved 3 comparisons, the level of statistical significance was set at 0.017 3 3 by using the Bonferroni multiple comparisons test. Finally, regression analysis was used to examine linearity between intake and changes. When the quadratic component was not statistically significant (P . 0.05), it was omitted from the model. was related to a further reduction in intestinal cholesterol absorption-would lead to a larger reduction in the lipophylic hydrocarbon carotenoids. However, the changes in cholesterolstandardized b-carotene concentrations did not confirm this assumption. We observed, however, a decrease in the plasma cholesterol-standardized b-carotene concentration of 9.2% between the 3-g and control groups. Although this difference was not statistically significant, it was in line with earlier studies (1) . At higher intakes, no additional effects were evident. This finding raises the question of whether effects of plant stanol esters on intestinal cholesterol absorption are caused by another mechanism than that underlying the reduction in serum carotenoids. Absorption of intestinal cholesterol is apparently NPC1L1-mediated (17), whereas absorption of carotenoids may be mediated by SRBI (18 (20) . Besides carotenoids, absolute a-tocopherol concentrations were lowered by plant stanol ester consumption. In agreement with studies using lower intakes, this effect disappeared after adjustment for changes in serum total cholesterol concentrations (1). This indicated that the reduction in serum a-tocopherol concentrations is mainly related to the number of lipoprotein particles (the carriers) in the circulation, as suggested previously (7) . The second aspect that needs to be considered is the increase in serum plant stanols concentrations, which was a priori expected to relate to intakes. Although the absorption of plant stanols is very low, especially in comparison with that of cholesterol, serum cholesterol-standardized sitostanol and campestanol concentrations increase when products enriched with plant stanols are consumed (7) . We found that the most pronounced increases in serum cholesterol-standardized plant stanol concentrations were found between the control group and the 3-g group. Concentrations increased further at higher intakes, but were less distinct. In other words, the increase in serum plant stanols did not follow the linear relation as observed for serum LDL-cholesterol reductions, but leveled off at intakes .3 g. Moreover, serum cholesterol-standardized plant stanols concentrations remained far below those of cholesterol-standardized plant sterols at any intake. As expected, plant stanol ester consumption lowered serum plant sterol concentrations. Again, the first 3 g of plant stanols induced the largest reductions, and the effects were less pronounced in the 6-g and 9-g groups. Why changes in serum plant stanol and sterol concentrations did not follow a linear relation with intake is difficult to explain, especially because changes in serum cholesterol-standardized serum plant sterols are considered markers of intestinal cholesterol absorption (21) , which is the proposed mechanism underlying the reductions in LDL cholesterol. The finding that the effects on LDL cholesterol were linear and those of cholesterol-standardized plant sterol concentrations were not suggests that additional mechanisms contribute to the observed LDL cholesterol-lowering effects at plant stanol intakes of 6 and 9 g.
Finally, observed no changes in markers reflecting liver and kidney function. Also, Gylling et al (13) found no effects on these markers at daily plant stanol intakes of 8.8 g. It can be argued, however, that the duration of both studies (ie, 4 and 10 wk) was too short to induce any effect on liver and kidney function indicators. Therefore, it might be necessary to carry out longerterm study at these higher intakes. Another issue that needs attention relates to the efficacy and safety of high plant stanol ester intakes in combination with frequently prescribed cholesterollowering drugs.
Another question is whether effects observed for plant stanols can be extrapolated to plant sterols. In their meta-analysis, Demonty et al (3) plotted the dose-response relation for plant sterol or stanol intake vs changes in serum LDL cholesterol. It was estimated that plant stanols had a 6.7% (95% CI: 218.3%, 5.0%) larger maximal LDL cholesterol-lowering effect than did plant sterols, although this difference was not statistically significant. In addition, the results of 3 earlier studies with high plant sterol intakes (ie, 6.6, 8.6, and 9.0 g), in which plant sterols were provided as fatty acid esters, were not consistent. Clifton et al (22) found that a daily intake of 6.6 g plant sterols provided in bread, cereals, and spreads for a period of 6 wk lowered serum LDL-cholesterol concentrations by 12.6%. Ayesh et al (23) found a reduction in LDL cholesterol of 0.58 mmol/L, or 18.3%, after 21-28 d consumption of 8.6 g plant sterols, provided through margarines. This effect may, however, have been slightly overestimated because the control margarine provided more cholesterol than did the experimental margarine. Finally, Davidson et al (24) reported a reduction of 0.41 mmol/L, or 9.0%, after 4 wk consumption of 9 g plant sterols, which were incorporated in fat-reduced spreads and salad dressings. Therefore, based on the currently available literature it is too early to entirely extrapolate our current findings to plant sterol esters.
In conclusion, daily consumption of plant stanols up to 9 g reduces serum LDL-cholesterol concentrations linearly up to 17.4%. For cholesterol-standardized fat-soluble antioxidant concentrations, such a relation could not be ascertained.
